• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2020年3月1日至6月30日期间，通过美国2019冠状病毒病相关住院监测网络确定的住院患者中正在使用的COVID-19研究性治疗方法。

COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020.

作者信息

Acosta Anna M, Mathis Adria L, Budnitz Daniel S, Geller Andrew I, Chai Shua J, Alden Nisha B, Meek James, Anderson Evan J, Ryan Patricia, Kim Sue, Como-Sabetti Kathryn, Torres Salina, Dufort Elizabeth, Bennett Nancy M, Billing Laurie M, Sutton Melissa, Keipp Talbot H, George Andrea, Pham Huong, Hall Aron J, Fry Alicia, Garg Shikha, Kim Lindsay

机构信息

COVID-NET Surveillance Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

All Native Synergies Company, Winnebago, Nebraska, USA.

出版信息

Open Forum Infect Dis. 2020 Nov 9;7(11):ofaa528. doi: 10.1093/ofid/ofaa528. eCollection 2020 Nov.

DOI:10.1093/ofid/ofaa528
PMID:33274249
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7686662/
Abstract

Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.

摘要

通过一个2019冠状病毒病（COVID-19）相关住院监测网络，我们发现，在2020年3月1日至6月30日有可用数据的住院COVID-19病例中，42.5%接受了≥1种COVID-19研究性治疗。羟氯喹、阿奇霉素和瑞德西韦使用频繁；然而，羟氯喹和阿奇霉素的使用随时间减少，而瑞德西韦的使用增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c6/7686662/305576ba0b54/ofaa528_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c6/7686662/305576ba0b54/ofaa528_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c6/7686662/305576ba0b54/ofaa528_fig1.jpg

相似文献

1
COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020.2020年3月1日至6月30日期间，通过美国2019冠状病毒病相关住院监测网络确定的住院患者中正在使用的COVID-19研究性治疗方法。
Open Forum Infect Dis. 2020 Nov 9;7(11):ofaa528. doi: 10.1093/ofid/ofaa528. eCollection 2020 Nov.
2
Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.药物流行病学、机器学习和 COVID-19：羟氯喹（无论是否联合阿奇霉素）治疗意向分析，及其对住院美国退伍军人 COVID-19 结局的影响。
Am J Epidemiol. 2021 Nov 2;190(11):2405-2419. doi: 10.1093/aje/kwab183.
3
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients.硫酸锌与锌离子载体联合应用可能改善住院 COVID-19 患者的结局。
J Med Microbiol. 2020 Oct;69(10):1228-1234. doi: 10.1099/jmm.0.001250. Epub 2020 Sep 15.
4
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹（无论是否联合使用阿奇霉素）导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
5
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.羟氯喹和托珠单抗治疗 COVID-19 患者：一项观察性研究。
PLoS One. 2020 Aug 13;15(8):e0237693. doi: 10.1371/journal.pone.0237693. eCollection 2020.
6
Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.模拟评估治疗儿童 COVID-19 的新型治疗方法的药代动力学指导剂量。
JAMA Pediatr. 2020 Oct 1;174(10):e202422. doi: 10.1001/jamapediatrics.2020.2422. Epub 2020 Oct 5.
7
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.羟氯喹、阿奇霉素和联合治疗 COVID-19 住院患者。
Int J Infect Dis. 2020 Aug;97:396-403. doi: 10.1016/j.ijid.2020.06.099. Epub 2020 Jul 2.
8
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.药物干预治疗 COVID-19 的疗效和安全性比较：系统评价和网络荟萃分析。
PLoS Med. 2020 Dec 30;17(12):e1003501. doi: 10.1371/journal.pmed.1003501. eCollection 2020 Dec.
9
Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials.COVID-19 住院患者中阿奇霉素和羟氯喹的疗效：随机对照试验的网络荟萃分析。
J Med Virol. 2021 Dec;93(12):6737-6749. doi: 10.1002/jmv.27259. Epub 2021 Aug 17.
10
Investigational medications in 9,638 hospitalized patients with severe COVID-19: lessons from the "fail-and-learn" strategy during the first two waves of the pandemic in 2020.9638例住院的重症新冠肺炎患者的试验性药物：2020年疫情前两波期间“失败并学习”策略的经验教训
Patient Saf Surg. 2023 Apr 11;17(1):7. doi: 10.1186/s13037-023-00358-9.

引用本文的文献

1
Prospective clinical surveillance for severe acute respiratory illness and COVID-19 vaccine effectiveness in Kenyan hospitals during the COVID-19 pandemic.肯尼亚医院在 COVID-19 大流行期间对严重急性呼吸道疾病和 COVID-19 疫苗有效性的前瞻性临床监测。
BMC Infect Dis. 2024 Nov 5;24(1):1246. doi: 10.1186/s12879-024-10140-6.
2
Unveiling the dynamics of antimicrobial utilization and resistance in a large hospital network over five years: Insights from health record data analysis.揭示大型医院网络中五年内抗菌药物使用与耐药性的动态变化：来自健康记录数据分析的见解
PLOS Digit Health. 2023 Dec 29;2(12):e0000424. doi: 10.1371/journal.pdig.0000424. eCollection 2023 Dec.
3

本文引用的文献

1
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
2
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
3
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
One Year Into the Pandemic: Evolving COVID-19 Outcomes in Lung Transplant Recipients, a Single-center Experience.
疫情爆发一年之际：肺移植受者中不断演变的新冠病毒感染结局，单中心经验
Transplant Direct. 2022 Feb 21;8(3):e1296. doi: 10.1097/TXD.0000000000001296. eCollection 2022 Mar.
4
A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020.2020 年美国重症监护病房收治儿童的 COVID-19 定向治疗描述。
J Pediatric Infect Dis Soc. 2022 May 30;11(5):191-198. doi: 10.1093/jpids/piab123.
5
Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States.美国2019冠状病毒病住院患者的临床管理
Open Forum Infect Dis. 2021 Sep 28;9(1):ofab498. doi: 10.1093/ofid/ofab498. eCollection 2022 Jan.
6
Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort.瑞德西韦治疗 2019 年冠状病毒病（COVID-19）住院患者：一项大型多中心观察性队列中院内全因死亡率的比较分析。
Clin Infect Dis. 2022 Aug 24;75(1):e450-e458. doi: 10.1093/cid/ciab875.
7
Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020.2020 年 3 月至 8 月期间，558 家美国医院中病例数激增与 COVID-19 患者存活率的关联。
Ann Intern Med. 2021 Sep;174(9):1240-1251. doi: 10.7326/M21-1213. Epub 2021 Jul 6.
8
Antimicrobial resistance and COVID-19: Intersections and implications.抗微生物药物耐药性与 COVID-19：交叉与影响。
Elife. 2021 Feb 16;10:e64139. doi: 10.7554/eLife.64139.
9
A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals.《2019冠状病毒病治疗史初稿：美国医院中旧药新用情况》
Open Forum Infect Dis. 2020 Dec 15;8(2):ofaa617. doi: 10.1093/ofid/ofaa617. eCollection 2021 Feb.
恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响：一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
4
Immunotherapies for COVID-19: lessons learned from sepsis.新冠病毒病的免疫疗法：脓毒症的经验教训
Lancet Respir Med. 2020 Oct;8(10):946-949. doi: 10.1016/S2213-2600(20)30217-4. Epub 2020 Apr 28.
5
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
6
Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.2020 年 3 月 1 日至 30 日，14 个州住院的经实验室确诊的 2019 冠状病毒病患者的住院率和特征 - COVID-NET。
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464. doi: 10.15585/mmwr.mm6915e3.
7
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
8
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
9
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.比较瑞德西韦与洛匹那韦利托那韦和干扰素β联合治疗中东呼吸综合征冠状病毒的疗效。
Nat Commun. 2020 Jan 10;11(1):222. doi: 10.1038/s41467-019-13940-6.